This is leading to widespread testing of RAS mutations in patients (such as the recent study in ovarian cancer [154]) and, indeed, is approved by the European Medicines Agency as an exclusion criterion for anti-EGFR therapy in colorectal cancer in Europe. Here, EGFR is linked to ovarian cancer.